Wall Street Zen Upgrades Attovia Therapeutics (NASDAQ:ATTO) to Sell

Posted by Brenda Bartman on Sep 21st, 2026

Attovia Therapeutics (NASDAQ:ATTO – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Other analysts also recently issued reports about the company. Citigroup began coverage on Attovia Therapeutics in a research report on Monday, August 31st. They set a “buy” rating and a $30.00 price target for the company. Zacks Research raised Attovia Therapeutics to a “hold” rating in a research report on Friday, September 4th. Morgan Stanley began coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They issued an “overweight” rating and a $39.00 price target on the stock. Lifesci Capital initiated coverage on shares of Attovia Therapeutics in a report on Monday, August 31st. They set an “outperform” rating and a $45.00 price objective for the company. Finally, Leerink Partners started coverage on shares of Attovia Therapeutics in a research note on Monday, August 31st. They issued an “outperform” rating and a $52.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $42.20.

Read Our Latest Analysis on Attovia Therapeutics

Attovia Therapeutics Stock Performance

Attovia Therapeutics stock opened at $22.14 on Friday. Attovia Therapeutics has a fifty-two week low of $16.15 and a fifty-two week high of $28.00.

Attovia Therapeutics (NASDAQ:ATTO – Get Free Report) last posted its quarterly earnings data on Wednesday, September 2nd. The company reported ($4.88) EPS for the quarter. The business had revenue of $0.45 million for the quarter. On average, equities research analysts expect that Attovia Therapeutics will post -4.06 earnings per share for the current year.

Insider Activity

In other news, major shareholder Life Sciences Xi L.P. Frazier purchased 588,235 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was bought at an average price of $17.00 per share, for a total transaction of $9,999,995.00. Following the purchase, the insider owned 6,154,213 shares of the company’s stock, valued at $104,621,621. The trade was a 10.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Global Strategic Fund I. Venbio acquired 382,352 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average cost of $17.00 per share, with a total value of $6,499,984.00. Following the acquisition, the insider owned 4,181,367 shares in the company, valued at $71,083,239. The trade was a 10.06% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 2,740,587 shares of company stock worth $47,269,979.

About Attovia Therapeutics

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated and inflammatory diseases. Its research programs are designed to address conditions in which dysregulated immune signaling contributes to disease.

The company’s activities include discovering, developing and advancing biologic drug candidates through preclinical and clinical testing. Attovia’s pipeline is centered on targeted therapies intended to modulate key pathways involved in inflammation and immune responses, with the goal of treating patients with significant unmet medical needs.

Attovia Therapeutics is headquartered in the United States and operates as a development-stage biopharmaceutical company.